364 related articles for article (PubMed ID: 33342303)
1. Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study.
Kingwell E; Zhang T; Zhu F; Walld R; Carruthers R; Evans C; Marrie RA; Tremlett H
Expert Opin Drug Saf; 2021 Apr; 20(4):481-487. PubMed ID: 33342303
[TBL] [Abstract][Full Text] [Related]
2. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
[TBL] [Abstract][Full Text] [Related]
3. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
4. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
7. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis.
Earla JR; Li J; Hutton GJ; Bentley JP; Aparasu RR
Mult Scler Relat Disord; 2024 May; 85():105539. PubMed ID: 38574721
[TBL] [Abstract][Full Text] [Related]
8. The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
Jivraj F; Kang S; Reedie S; Kapadia S; Strzok S; Elliott E; Cano S; Rock M
Adv Ther; 2022 Nov; 39(11):5072-5086. PubMed ID: 36053450
[TBL] [Abstract][Full Text] [Related]
9. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
10. Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Gil-Bernal R; González-Caballero JL; Espinosa-Rosso R; Gómez-Gómez C
Sci Rep; 2021 Jun; 11(1):12533. PubMed ID: 34131191
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
[TBL] [Abstract][Full Text] [Related]
12. Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
Desai RJ; Mahesri M; Gagne JJ; Hurley E; Tong A; Chitnis T; Minden S; Spettell CM; Matlin OS; Shrank WH; Choudhry NK
J Manag Care Spec Pharm; 2019 Jan; 25(1):113-121. PubMed ID: 30589630
[TBL] [Abstract][Full Text] [Related]
13. Real-life use of oral disease-modifying treatments in Austria.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
[TBL] [Abstract][Full Text] [Related]
14. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
[TBL] [Abstract][Full Text] [Related]
15. Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
Pappolla A; Auger C; Sao-Aviles A; Tur C; Rodriguez-Barranco M; Cobo-Calvo Á; Mongay-Ochoa N; Rodríguez-Acevedo B; Zabalza A; Midaglia L; Carbonell-Mirabent P; Carvajal R; Castilló-Justribó J; Braga N; Bollo L; Vidal-Jordana A; Arrambide G; Nos C; Salerno A; Galán I; Comabella M; Sastre-Garriga J; Tintoré M; Rovira A; Montalban X; Río J
Mult Scler; 2024 Jun; 30(7):820-832. PubMed ID: 38551315
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.
Zivadinov R; Kresa-Reahl K; Weinstock-Guttman B; Edwards K; Burudpakdee C; Bergsland N; Dwyer MG; Khatri B; Thangavelu K; Chavin J; Mandel M; Cohan S
J Comp Eff Res; 2019 Apr; 8(5):305-316. PubMed ID: 30754997
[TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis hospitalizations among users of oral disease-modifying therapies.
Pham Nguyen TP; Jacobs D; Thibault D; Willis AW
Mult Scler Relat Disord; 2021 Jul; 52():102944. PubMed ID: 33894480
[TBL] [Abstract][Full Text] [Related]
18. Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework.
Brnabic AJM; Curtis SE; Johnston JA; Lo A; Zagar AJ; Lipkovich I; Kadziola Z; Murray MH; Ryan T
PLoS One; 2024; 19(3):e0300708. PubMed ID: 38517926
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
[TBL] [Abstract][Full Text] [Related]
20. Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
Ng HS; Kingwell E; Zhu F; Zhang T; Marrie RA; Carruthers R; Tremlett H
Mult Scler; 2021 Feb; 27(2):239-249. PubMed ID: 32141376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
